Use of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors for Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Metastatic Breast Cancer: a Roundtable Discussion by The Breast Cancer Therapy Expert Group (BCTEG)

Reshma Mahtani; Jame Abraham; Robert Coleman; Anthony Elias; Frankie Ann Holmes; Kevin Kalinsky; Muaiad Kittaneh; Elyse Lower; E. Terry Mamounas; Mark Pegram; Charles L. Vogel; Breast Cancer Therapy Expert Group (BCTEG)

Use of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors for Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Metastatic Breast Cancer: a Roundtable Discussion by The Breast Cancer Therapy Expert Group (BCTEG)

Reshma Mahtani, Jame Abraham, Robert Coleman, Anthony Elias, Frankie Ann Holmes, Kevin Kalinsky, Muaiad Kittaneh, Elyse Lower, E. Terry Mamounas, Mark Pegram, Charles L. Vogel, Breast Cancer Therapy Expert Group (BCTEG)

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Breast cancer research and treatment
Volume	171
State	Published - May 4 2018

Disciplines

Medicine and Health Sciences

Cite this

Mahtani, R., Abraham, J., Coleman, R., Elias, A., Holmes, F. A., Kalinsky, K., Kittaneh, M., Lower, E., Mamounas, E. T., Pegram, M., Vogel, C. L., & (BCTEG), B. C. T. E. G. (2018). Use of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors for Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Metastatic Breast Cancer: a Roundtable Discussion by The Breast Cancer Therapy Expert Group (BCTEG). Breast cancer research and treatment, 171.

Use of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors for Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Metastatic Breast Cancer: a Roundtable Discussion by The Breast Cancer Therapy Expert Group (BCTEG). / Mahtani, Reshma; Abraham, Jame; Coleman, Robert et al.
In: Breast cancer research and treatment, Vol. 171, 04.05.2018.

Research output: Contribution to journal › Article › peer-review

Mahtani, R, Abraham, J, Coleman, R, Elias, A, Holmes, FA, Kalinsky, K, Kittaneh, M, Lower, E, Mamounas, ET, Pegram, M, Vogel, CL & (BCTEG), BCTEG 2018, 'Use of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors for Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Metastatic Breast Cancer: a Roundtable Discussion by The Breast Cancer Therapy Expert Group (BCTEG)', Breast cancer research and treatment, vol. 171.

@article{b7529fa5c88c4a049e2a0dc5d64c506b,

title = "Use of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors for Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Metastatic Breast Cancer: a Roundtable Discussion by The Breast Cancer Therapy Expert Group (BCTEG)",

author = "Reshma Mahtani and Jame Abraham and Robert Coleman and Anthony Elias and Holmes, \{Frankie Ann\} and Kevin Kalinsky and Muaiad Kittaneh and Elyse Lower and Mamounas, \{E. Terry\} and Mark Pegram and Vogel, \{Charles L.\} and (BCTEG), \{Breast Cancer Therapy Expert Group\}",

note = "Thus far, three CDK 4/6 inhibitors-palbociclib, ribociclib, and more recently, abemaciclib-have been approved for use in the setting of HR+, HER2-, mBC. The degrees to which these agents differ in terms of CDK4/6 affinity, side-effect profiles, dosing, degree of central nervous system (CNS) penetrat ...",

year = "2018",

month = may,

day = "4",

language = "American English",

volume = "171",

journal = "Breast cancer research and treatment",

}

TY - JOUR

T1 - Use of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors for Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Metastatic Breast Cancer: a Roundtable Discussion by The Breast Cancer Therapy Expert Group (BCTEG)

AU - Mahtani, Reshma

AU - Abraham, Jame

AU - Coleman, Robert

AU - Elias, Anthony

AU - Holmes, Frankie Ann

AU - Kalinsky, Kevin

AU - Kittaneh, Muaiad

AU - Lower, Elyse

AU - Mamounas, E. Terry

AU - Pegram, Mark

AU - Vogel, Charles L.

AU - (BCTEG), Breast Cancer Therapy Expert Group

N1 - Thus far, three CDK 4/6 inhibitors-palbociclib, ribociclib, and more recently, abemaciclib-have been approved for use in the setting of HR+, HER2-, mBC. The degrees to which these agents differ in terms of CDK4/6 affinity, side-effect profiles, dosing, degree of central nervous system (CNS) penetrat ...

PY - 2018/5/4

Y1 - 2018/5/4

UR - https://pubmed.ncbi.nlm.nih.gov/29725889/

M3 - Article

VL - 171

JO - Breast cancer research and treatment

JF - Breast cancer research and treatment

ER -

Use of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors for Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Metastatic Breast Cancer: a Roundtable Discussion by The Breast Cancer Therapy Expert Group (BCTEG)

Disciplines

Other files and links

Cite this